Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity

OncoImmunology

Volumn 5, Issue 12, 2016, Pages

  Hu, Xiao ^a   Liu, Xikui ^a   Moisan, Jacques ^a   Wang, Yahong ^a   Lesch, Charles A ^a   Spooner, Chauncey ^a   Morgan, Rodney W ^a   Zawidzka, Elizabeth M ^a   Mertz, David ^a   Bousley, Dick ^a   Majchrzak, Kinga ^b   Kryczek, Ilona ^c   Taylor, Clarke ^a   Van Huis, Chad ^a   Skalitzky, Don ^a   Hurd, Alexander ^a   Aicher, Thomas D ^a   Toogood, Peter L ^a   Glick, Gary D ^a   Paulos, Chrystal M ^b   Zou, Weiping ^c   Carter, Laura L ^a   more..

^a Lycera Corporation   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adoptive cell therapy; co inhibitory receptors; co stimulatory receptors; immunotherapy; PD 1; ROR ; Tc17; Th17

Indexed keywords

CD137 ANTIGEN; CD3 ANTIGEN; CD37 ANTIGEN; CD39 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DESMOSTEROL; INTERLEUKIN 17; PROGRAMMED DEATH 1 RECEPTOR; RETINOID RELATED ORPHAN RECEPTOR GAMMA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL SURVIVAL; CELL THERAPY; CYTOLYSIS ASSAY; CYTOTOXICITY; CYTOTOXICITY ASSAY; EC50; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LUCIFERASE ASSAY; MOUSE; NONHUMAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 85006263042     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1254854     Document Type: Article

References (47)

1. Cua DJ, Tato CM. Innate IL-17-producing cells:the sentinels of the immune system. Nat Rev Immunol 2010; 10:479-89; PMID:20559326; http://dx.doi.org/10.1038/nri2800
2. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126:1121-33; PMID:16990136; http://dx.doi.org/10.1016/j.cell.2006.07.035
3. Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, Magnenat L, Suter T, Becher B. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011; 12:560-7; PMID:21516112; http://dx.doi.org/10.1038/ni.2027
4. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORgammat. Nat Immunol 2008; 9:641-9; PMID:18454151; http://dx.doi.org/10.1038/ni.1610
5. Dong C. Differentiation and function of pro-inflammatory Th17 cells. Microbes Infect / Institut Pasteur 2009; 11:584-8; PMID:19371793; http://dx.doi.org/10.1016/j.micinf.2009.04.001
6. Sun Z, Unutmaz D, Zou YR, Sunshine MJ, Pierani A, Brenner-Morton S, Mebius RE, Littman DR. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science 2000; 288:2369-73; PMID:10875923; http://dx.doi.org/10.1126/science.288.5475.2369
7. Guo J, Hawwari A, Li H, Sun Z, Mahanta SK, Littman DR, Krangel MS, He YW. Regulation of the TCRalpha repertoire by the survival window of CD4(+)CD8(+) thymocytes. Nat Immunol 2002; 3:469-76; PMID:11967541; http://dx.doi.org/10.1038/ni791
8. Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B, Wrzesinski C, Borman ZA, Muranski P, Restifo NP. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 2009; 114:596-9; PMID:19471017; http://dx.doi.org/10.1182/blood-2009-02-203935
9. Garcia-Hernandez Mde L, Hamada H, Reome JB, Misra SK, Tighe MP, Dutton RW. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol 2010; 184:4215-27; PMID:20237297; http://dx.doi.org/10.4049/jimmunol.0902995
10. Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011; 35:972-85; PMID:22177921; http://dx.doi.org/10.1016/j.immuni.2011.09.019
11. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009; 114:1141-9; PMID:19470694; http://dx.doi.org/10.1182/blood-2009-03-208249
12. Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD, Jr, Scholler J, Scholler N, et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 2014; 124:1070-80; PMID:24986688; http://dx.doi.org/10.1182/blood-2013-10-535245
13. Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, Carroll RG, Riley JL, June CH. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Translational Med 2010; 2:55ra78; PMID:20980695; http://dx.doi.org/10.1126/scitranslmed.3000448
14. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10:248-56; PMID:20336152; http://dx.doi.org/10.1038/nri2742
15. Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, Moyer J, Klimczak A, Lange A, Zou W. Human TH17 cells are long-lived effector memory cells. Sci Translational Med 2011; 3:104ra0; PMID:21998407; http://dx.doi.org/10.1126/scitranslmed.3002949
16. Hu X, Wang Y, Hao LY, Liu X, Lesch CA, Sanchez BM, Wendling JM, Morgan RW, Aicher TD, Carter LL, et al. Sterol metabolism controls TH17 differentiation by generating endogenous RORgamma agonists. Nat Chem Biol 2015; 11:141-7; PMID:25558972; http://dx.doi.org/10.1038/nchembio.1714
17. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8; PMID:16648838; http://dx.doi.org/10.1038/nature04753
18. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, Shah B, Chang SH, Schluns KS, Watowich SS, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29:44-56; PMID:18585065; http://dx.doi.org/10.1016/j.immuni.2008.05.007
19. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
20. Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer 2014; 111:2214-9; PMID:25211661; http://dx.doi.org/10.1038/bjc.2014.348
21. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007; 27:670-84; PMID:17950003; http://dx.doi.org/10.1016/j.immuni.2007.09.006
22. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, Ladoire S, Derangere V, Vincent J, Masson D, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012; 36:362-73; PMID:22406269; http://dx.doi.org/10.1016/j.immuni.2011.12.019
23. Chatterjee S, Thyagarajan K, Kesarwani P, Song JH, Soloshchenko M, Fu J, Bailey SR, Vasu C, Kraft AS, Paulos CM, et al. Reducing CD73 expression by IL1beta-Programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res 2014; 74:6048-59; PMID:25205101; http://dx.doi.org/10.1158/0008-5472.CAN-14-1450
24. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annual Rev Med 2014; 65:333-47; PMID:24274181; http://dx.doi.org/10.1146/annurev-med-060512-150254
25. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014; 2:112-20; PMID:24579088; http://dx.doi.org/10.1158/2326-6066.CIR-13-0170
26. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005; 65:1089-96; PMID:15705911
27. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11:728-34; PMID:15701862
28. Hirahara K, Ghoreschi K, Laurence A, Yang XP, Kanno Y, O'Shea JJ. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev 2010; 21:425-34; PMID:21084214; http://dx.doi.org/10.1016/j.cytogfr.2010.10.006
29. Shapiro M, Nandi B, Pai C, Samur MK, Pelluru D, Fulciniti M, Prabhala RH, Munshi NC, Gold JS. Deficiency of IL-17A, but not the prototypical Th17 transcription factor RORgammat, decreases murine spontaneous intestinal tumorigenesis. Cancer Immunol Immunotherapy 2016; 65:13-24; PMID:26559812; http://dx.doi.org/10.1007/s00262-015-1769-2
30. Hirahara N, Nio Y, Sasaki S, Minari Y, Takamura M, Iguchi C, Dong M, Yamasawa K, Tamura K. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 2001; 61:79-89; PMID:11474253; http://dx.doi.org/10.1159/000055357
31. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002; 99:2114-21; PMID:11877287; http://dx.doi.org/10.1182/blood.V99.6.2114
32. Arellano M, Lonial S. Clinical uses of GM-CSF, a critical appraisal and update. Biologics:Targets Therapy 2008; 2:13-27; PMID:19707424; http://dx.doi.org/10.2147/BTT.S1355
33. Kwek SS, Kahn J, Greaney SK, Lewis J, Cha E, Zhang L, Weber RW, Leonard L, Markovic SN, Fong L, et al. GM-CSF and ipilimumab therapy in metastatic melanoma:Clinical outcomes and immunologic responses. Oncoimmunology 2016; 5:e1101204; PMID:27141383; http://dx.doi.org/10.1080/2162402X.2015.1101204
34. Sefik E, Geva-Zatorsky N, Oh S, Konnikova L, Zemmour D, McGuire AM, Burzyn D, Ortiz-Lopez A, Lobera M, Yang J, et al. Mucosal Immunology. Individual intestinal symbionts induce a distinct population of RORgamma(+) regulatory T cells. Science 2015; 349:993-7; PMID:26272906; http://dx.doi.org/10.1126/science.aaa9420
35. Ohnmacht C, Park JH, Cording S, Wing JB, Atarashi K, Obata Y, Gaboriau-Routhiau V, Marques R, Dulauroy S, Fedoseeva M, et al. Mucosal Immunology. The microbiota regulates type 2 immunity through RORgammat(+) T cells. Science 2015; 349:989-93; PMID:26160380; http://dx.doi.org/10.1126/science.aac4263
36. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015; 15:486-99; PMID:26205583; http://dx.doi.org/10.1038/nri3862
37. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT:Co-inhibitory receptors with specialized functions in immune regulation. Immunity 2016; 44:989-1004; PMID:27192565; http://dx.doi.org/10.1016/j.immuni.2016.05.001
38. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13:227-42; PMID:23470321; http://dx.doi.org/10.1038/nri3405
39. Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 2009; 106:17858-63; PMID:19815499; http://dx.doi.org/10.1073/pnas.0903474106
40. Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, Ritchie DS, Colonna M, Andrews DM, Smyth MJ. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 2014; 15:431-8; PMID:24658051; http://dx.doi.org/10.1038/ni.2850
41. Johnston RJ, Yu X, Grogan JL. The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses. Oncoimmunology 2015; 4:e1036214; PMID:26405604; http://dx.doi.org/10.1080/2162402X.2015.1036214
42. Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol 2012; 188:3869-75; PMID:22427644; http://dx.doi.org/10.4049/jimmunol.1103627
43. Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME, Jure-Kunkel M, Melero I. Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Seminars Oncol 2015; 42:640-55; PMID:26320067; http://dx.doi.org/10.1053/j.seminoncol.2015.05.014
44. Young A, Mittal D, Stagg J, Smyth MJ. Targeting cancer-derived adenosine:new therapeutic approaches. Cancer Discovery 2014; 4:879-88; PMID:25035124; http://dx.doi.org/10.1158/2159-8290.CD-14-0341
45. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors:persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14:1264-70; PMID:18978797; http://dx.doi.org/10.1038/nm.1882
46. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ, Jr, Rosenberg SA. Cutting edge:persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004; 173:7125-30; PMID:15585832; http://dx.doi.org/10.4049/jimmunol.173.12.7125
47. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 2013; 1:229-34; PMID:24777852; http://dx.doi.org/10.1158/2326-6066.CIR-13-0020